Cefaly Technology has launched the CeCe Migraine Management app, designed to empower users with enhanced control over their Cefaly Connected neuromodulation device treatments.

The new app allows for two-way communication between the user’s smartphone and the Cefaly device.

Initially introduced in 2021, the CeCe app has evolved to become a comprehensive tool for migraine sufferers.

With the latest update, users can now start, stop, adjust, and track neuromodulation migraine treatments directly from their phones.

The app also enables users to track their treatments, and understand their migraine patterns.

Cefaly said the app’s development was a collaborative effort with BairesDev, a software development company.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The app’s interface is designed to be intuitive and sensitive to the needs of individuals experiencing migraines, incorporating advanced cybersecurity measures to protect health data.

Cefaly has also worked with regulatory and quality compliance consultant Elexes for four years. This collaboration has been instrumental in securing expanded capabilities for the Cefaly Connected device, enabling the CeCe app to function as an accessory.

Approved by the US Food and Drug Administration (FDA), the Cefaly over-the-counter wearable medical device has been proven clinically to help reduce the frequency of migraine and relieve pain.

It operates by delivering low-intensity electrical impulses to stimulate and desensitise the trigeminal nerve. The device offers two modes: ACUTE for pain relief, and PREVENT to reduce the frequency of attacks.

Cefaly Technology CEO Jen Trainor McDermott said: “Migraine can be such an unpredictable and debilitating disorder, and many people feel that migraine controls their lives.

“The new CeCe app turns the tables by giving people full control of their migraine treatments. Being able to fine-tune your neuromodulation sessions in real-time, as well as seeing your unique migraine patterns and tracking your treatment progress, is a game-changer.”